Literature DB >> 19362372

Role of phosphoinositide 3-kinase p110 delta in TLR4- and TLR9-mediated B cell cytokine production and differentiation.

Nyla Dil1, Aaron J Marshall.   

Abstract

Phosphoinositide 3-kinase (PI3K) enzymes play key roles in signaling via antigen receptors and cytokine receptors and isoform-selective PI3K inhibitors are being evaluated as targets for treatment of allergic and inflammatory diseases. The specific roles of PI3K isoforms in TLR-mediated activation of lymphocytes have not been defined. In this study we assess the role of p110 delta PI3K in TLR4, TLR9, or TLR4+TLR9-mediated B cell responses. Utilizing both p110 delta-mutant mice and p110 delta-specific inhibitor IC87114, we find that signaling via p110 delta is required for optimal B cell proliferation, but is not required for TLR-mediated B cell differentiation into plasma cells or Ig isotype switch. However PI3K blockade led to increased frequencies of IgG1 and IgE expressing cells, and partially reversed ability of CpG to inhibit IgG1 and IgE. Examination of B cell cytokine production revealed that p110 delta blockade markedly reduced IL-6 and IL-10 production. In contrast, p110 delta signaling was clearly not required for IL-12 production, with p110 delta-mutant B cells in fact showing enhanced IL-12 p70 production. TLR4- and TLR9-ligands act in synergy to drive IL-6 and IL-10 production, but not IL-12, and this additive effect is independent of p110 delta signaling. Together, these results indicate that PI3K delta functions in influencing the type of B cell cytokine production and differentiation response induced by TLR-ligands.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19362372     DOI: 10.1016/j.molimm.2009.03.010

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  24 in total

Review 1.  Toll-like receptors--sentries in the B-cell response.

Authors:  Isabelle Bekeredjian-Ding; Gaetan Jego
Journal:  Immunology       Date:  2009-11       Impact factor: 7.397

2.  Phosphatidylinositol-3-kinase activity during in vitro dendritic cell generation determines suppressive or stimulatory capacity.

Authors:  Valentina Di Caro; Antonella D'Anneo; Brett Phillips; Carl Engman; Jo Harnaha; Massimo Trucco; Nick Giannoukakis
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

Review 3.  PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances.

Authors:  Lomon So; David A Fruman
Journal:  Biochem J       Date:  2012-03-15       Impact factor: 3.857

4.  Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.

Authors:  Sarah E M Herman; Amber L Gordon; Amy J Wagner; Nyla A Heerema; Weiqiang Zhao; Joseph M Flynn; Jeffrey Jones; Leslie Andritsos; Kamal D Puri; Brian J Lannutti; Neill A Giese; Xiaoli Zhang; Lai Wei; John C Byrd; Amy J Johnson
Journal:  Blood       Date:  2010-06-03       Impact factor: 22.113

Review 5.  The PI3K pathway in B cell metabolism.

Authors:  Julia Jellusova; Robert C Rickert
Journal:  Crit Rev Biochem Mol Biol       Date:  2016-08-05       Impact factor: 8.250

6.  Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.

Authors:  Susan O'Brien; Manish Patel; Brad S Kahl; Steven M Horwitz; Francine M Foss; Pierluigi Porcu; Jeffrey Jones; Jan Burger; Nitin Jain; Kerstin Allen; Kerrie Faia; Mark Douglas; Howard M Stern; Jennifer Sweeney; Patrick Kelly; Virginia Kelly; Ian Flinn
Journal:  Am J Hematol       Date:  2018-10-20       Impact factor: 10.047

7.  Activating mutations in PIK3CD disrupt the differentiation and function of human and murine CD4+ T cells.

Authors:  Julia Bier; Geetha Rao; Kathryn Payne; Henry Brigden; Elise French; Simon J Pelham; Anthony Lau; Helen Lenthall; Emily S J Edwards; Joanne M Smart; Theresa S Cole; Sharon Choo; Avni Y Joshi; Roshini S Abraham; Michael O'Sullivan; Kaan Boztug; Isabelle Meyts; Paul E Gray; Lucinda J Berglund; Peter Hsu; Melanie Wong; Steven M Holland; Luigi D Notarangelo; Gulbu Uzel; Cindy S Ma; Robert Brink; Stuart G Tangye; Elissa K Deenick
Journal:  J Allergy Clin Immunol       Date:  2019-02-06       Impact factor: 10.793

8.  p110Delta Inhibits Monocyte Infiltration by Thioglycollate-Induced Periotoneal Inflammation but Not HCD-Induced Inflammation and Atherosclerosis in APOE KO Mice.

Authors:  Futian Tang; Xiaoqiang Li; Yali Gui; Cuiling Qi; Meili Lu; Chunmei Dai; Hongxin Wang; Lijing Wang
Journal:  Lipids       Date:  2015-05-12       Impact factor: 1.880

9.  Insulin modulates the inflammatory granulocyte response to streptococci via phosphatidylinositol 3-kinase.

Authors:  Sybille Kenzel; Miriam Mergen; Julius von Süßkind-Schwendi; Julia Wennekamp; Sachin D Deshmukh; Monika Haeffner; Antigoni Triantafyllopoulou; Sebastian Fuchs; Susan Farmand; Sandra Santos-Sierra; Jochen Seufert; Timo K van den Berg; Taco W Kuijpers; Philipp Henneke
Journal:  J Immunol       Date:  2012-09-26       Impact factor: 5.422

10.  Lumen LPS inhibits HCO3(-) absorption in the medullary thick ascending limb through TLR4-PI3K-Akt-mTOR-dependent inhibition of basolateral Na+/H+ exchange.

Authors:  Bruns A Watts; Thampi George; David W Good
Journal:  Am J Physiol Renal Physiol       Date:  2013-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.